European Cancer Patient Coalition Attend European Pharmaceutical Summit Looking for Answers
By on Aug 29, 2013
comments powered by Disqus
The ECPC will join 11 other patient groups at Europe’s biggest annual pharmaceutical conference in an attempt to solidify their working relationship with industry groups that they often find themselves at odds with.
Kathi Apostolidis, Vice President of the ECPC has expressed her intentions to present the organisation’s expectations for future partnerships to the industry in an open session involving senior executives and decision makers from big pharma in an attempt to thrash out on-going issues that impact on fruitful collaboration, to the detriment of patients and industry alike. The debate will cover adherence, patient psychology, support programmes, services ‘beyond the pill’, communication, engagement and social media, with 200 members of the pharma, patient and stakeholder community sharing ideas.
Speaking ahead of the October event, Kathi Apostolidis outlined her intentions:
"At the European Cancer Patient Coalition, we believe that only close collaboration of researchers, pharma, clinicians and patients can lead to more efficient, accessible and less toxic cancer therapies. Patients should be included in research design and clinical trials from the concept stage."
"We consider it of utmost importance that pharma directly engages, consults with, listens to and understands cancer patient concerns and needs, as only then they will be able to produce better medicines and provide meaningful support. We're looking forward to the eyeforpharma 10th annual patient group to discuss with pharma how to understand patients and engage with patient groups to achieve this goal."
The eyeforpharma Patient Summit is Europe’s largest pharma-patient forum and attracts attendees from big and small pharma as well as many stakeholders. This year it celebrates its 10th Anniversary, and is co-located with another event entitled 'Value Added Services'.
For more details and to register visit: www.eyeforpharma.com/patient
Additional Information:
Paul Simms
eyeforpharma